

ASX Release

Contract Manufacturing Firm WuXi AppTec Announces Rationalisation Plan

Melbourne, Australia; 3 December, 2008: Australia's natural human antibody therapy company, Patrys Limited (ASX: PAB), learned today that effective 31 December 2008, its current contract manufacturing firm, WuXi AppTec, will terminate certain manufacturing functions as a part of a global rationalisation plan announced by Wuxi AppTec on 2 December 2008.

In discussions between the parties held today, Patrys received assurances that WuXi AppTec will continue to perform manufacturing services for Patrys that should produce sufficient antibody material to support Patrys' first-in-human clinical trials for lead products PAT-LM1 and PAT-SM6, planned for 2009.

-Ends-

For more information

Patrys Limited

Daniel Devine
Chief Executive Officer
P: +613 9670 3273 or
info@patrys.com

Media

Catie Corcoran
Buchan Consulting
P: +61 3 9866 4722 or
ccorcoran@bcg.com.au

Investor

Rebecca Wilson
Buchan Consulting
P: +61 417 382 391 or
rwilson@bcg.com.au

About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the commercialisation of its proprietary platform technologies for the capture, production, and development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies, two of which are scheduled to enter human clinical trials starting in 2009. In addition to its internal programs, Patrys has collaborations with several larger pharmaceutical companies to advance additional anti-cancer products from its pipeline. For further information about Patrys, please refer to www.patrys.com.

For personal use only